Akasa Air aims to have 226 planes by 2032, targets 25-30% growth yoy
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
Indian airline Akasa Air aims to achieve a 226-plane fleet by 2032, with an annual capacity addition of 25-30%, the airline's Chief Financial Officer Ankur Goel said on Tuesday.The airline is focused on cost leadership in the aviation sector as it is working on reducing unit cost in the current fiscal year.Akasa Air has placed an order for Boeing 737-10 aircraft with 227 seating capacity. The company expects the delivery of these aircraft by 2027.For now, the company is adding more 197-seater aircraft for capacity building as the company currently operates with 185-189-seater aircraft.To meet regional demands, Akasa Air deployed 1/4th capacity in Uttar Pradesh market during Maha Kumbh Mela 2025, Goel stated.The airline aims to have 226 aircraft by 2032, Goel said, adding that the fleet capacity growth will be around 25-30% CAGR (Compound Annual Growth Rate) in the seven-year period.Launched in August 2022, Akasa Air currently flies to 23 domestic and international destinations with a fleet of 30 Boeing 737 MAX planes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
9 minutes ago
- Mint
Indian shares inch lower as Kotak earnings drag financials, trade deal delay weighs
By Bharath Rajeswaran and Vivek Kumar M (Reuters) -Indian shares inched lower on Monday as weak results from Kotak Mahindra Bank weighed on sentiment, while uncertainty over trade talks with the U.S. added to overall caution. The Nifty 50 fell 0.16% to 24,798.9 points and the BSE Sensex lost 0.2% to 81,325.4 as of 10:03 a.m. IST. The broader small-caps and mid-caps lost 0.3% and 0.2%, respectively. Negotiations between India and the United States remained deadlocked over tariff cuts on agriculture and dairy products, dimming hopes of an interim deal ahead of U.S. President Donald Trump's August 1 deadline. This is in contrast to a framework trade agreement struck between the U.S. and European Union over the weekend, easing fears of a bigger trade war between the two allies, which account for almost a third of global trade. High-weightage financials and private banks lost 0.2% and 1%, respectively, dragged by a 7% fall in Kotak Mahindra Bank after it posted a drop in quarterly profit. The IT index lost 0.5%, with Tata Consultancy Services shedding 1.6% after it announced plans to reduce its workforce by 2% in fiscal year 2026. The Nifty 50 and 30-stock Sensex have logged four consecutive weekly losses due to weak earnings, foreign outflows and uncertainty over the U.S.-India trade deal. "A dull earnings season and the lingering delay in the India-U.S. trade deal have clearly cast a shadow on market sentiment. With valuations still stretched across the board, investors are understandably treading with heightened caution," said G Chokkalingam, founder and head of research at Equinomics Research. Among individual stocks, Mphasis gained 2.4% on posting quarterly results in-line with estimates and on strong deal bookings, which has boosted the IT company's revenue growth outlook. SBI Cards and Payment Services lost 3.7% after missing profit estimates in the June quarter. (Reporting by Vivek Kumar M and Bharath Rajeswaran; Editing by Eileen Soreng and Mrigank Dhaniwala)
Mint
9 minutes ago
- Mint
‘Serious hygiene issues in India…not racist to address': US Youtuber says he fell ill after eating at 5-star hotels
American Youtuber Tyler Oliveria recalled his India trip where he claimed to have faced hygiene issues after eating at 5-star hotels which 'source eggs from a filthy chicken farm' located next to a mountain of trash. He said he suffered four types of Salmonella due to it and was not doing racism to address the matter. Tyler got involved into whataboutery when an Indian woman called out foreign tourists, especially white travellers, for what she described as deliberately going to most 'unsanitary trains and buses' and "living worse than the way underprivileged people in India live' while visiting India to reinforce negative stereotypes. She added they go to unhygienic locations and comeback to post about how 'pathetic' India is. 'During my trip to India, I ONLY ate in 5 star hotels and still contracted 4 types of Salmonella. The hotel apparently sourced their eggs from a filthy chicken farm right next to a literal mountain of trash. There are serious hygiene issues that must be addressed in India. It is NOT racist to address the poor quality of life most Indians are subjected to while the upper caste insulates themselves from reality,' Tyler said. Many remarked in the comment section that he was 'defaming' the country. To put an end to criticism of what he described, the youtuber went on to share his medical reports as well. He further reacted to a user's comment, 'The 5 star hotels were about $100 a night. It was budget travel relative to American standards. Ambani has a billion dollar tower overlooking the slums. Your anger is misplaced.' Tyler didn't stop here and later shared a video showcasing 'largest chicken & egg market next to trash-infested landfill...' in Delhi. He mentioned, 'It smells pretty bad here. Look at those flies just eating away. The shrimp I ate at the hotel from here probably right.' Another confirmed, 'all from here'. He shows 'blood on the floor, bunch of flies, rats' and can be heard saying his cameraman was coughing due to the condition there. ( couldn't independently verify the authenticity of the video)
Economic Times
9 minutes ago
- Economic Times
Market in consolidation mode; triggers needed, says Sunil Subramaniam
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads "Another reason for pharma's past underperformance is that FIIs were driving the selling pressure. They closely track export-oriented sectors. So the recent post-results bounce in pharma is largely driven by DIIs. FIIs still haven't firmed up their stance on India. They remain a bit cautious, especially because the delay in the BTA (Bilateral Trade Agreement) hasn't helped sentiment," says Sunil Subramaniam , Market like you said, the question is—why were they under pressure in the first place? I'd call it the Trump effect. Mr. Trump has been talking a lot about imposing heavy pharma tariffs. He hasn't actually done anything yet, but every time he makes such statements, it creates nervousness—whether he's targeting CDMO players or generics, and how he plans to go about it. That uncertainty has impacted the pharma sector, putting it under when individual companies are reporting good numbers, the market has no choice but to buy into them—because at least those companies are indicating a positive outlook. Plus, some of them may not even be impacted by tariffs, creating a window of opportunity. Also, the pharma space includes domestic-oriented businesses like hospitals and diagnostics, which are unaffected by U.S. tariff issues. So overall, pharma remains a defensive reason for pharma's past underperformance is that FIIs were driving the selling pressure. They closely track export-oriented sectors. So the recent post-results bounce in pharma is largely driven by DIIs. FIIs still haven't firmed up their stance on India. They remain a bit cautious, especially because the delay in the BTA (Bilateral Trade Agreement) hasn't helped we need to understand the market's movement over the last three months. Post-March, FIIs were actually buyers in April and May, and even in June, though to a lesser extent. Meanwhile, if you look at the end of March, mutual fund DIIs—especially domestic mutual funds—had built up cash positions to around 7.25% of their April and May, both mutual funds and FIIs were buying, which supported the market. But starting this month, mutual fund cash levels are back down to around 5%, which is close to their lower limit. That means DIIs don't have as much cash left to deploy, apart from the fresh SIP looking at last earnings season and market levels, domestic funds have largely deployed their cash. FIIs, on the other hand, had expected some action around the BTA by July 9, which then got pushed to August 1. But now, even that deadline seems unlikely to be met. The Indian trade delegation has returned from the U.S. without a deal. Sticking points remain—like agriculture—and they won't be easy to the question now is whether Trump will extend the 10% tariff pause beyond August 1 or slap a 26% tariff on India and then negotiate, like he did with Japan—imposing higher tariffs first and then signing a deal at 19%. That kind of uncertainty around the India-U.S. BTA is keeping FIIs factor is China. While China and the U.S. haven't signed a full BTA either, they seem to have reached some understanding. Meanwhile, China's markets have been beaten down so much that the one-year forward P/E is around 11—compared to India's 22. And China's economy is about 4.5 times larger than India's. Even at 4% growth, those are big numbers. So FIIs are starting to see more value in China, pulling some attention away from as for your question on the next trigger—clearly, a breakthrough on the BTA front, like an interim deal or assurance that tariffs will be capped below 20%, could bring FIIs back. On the domestic side, it's the ongoing earnings season. Results have been mixed. The IT sector, for instance, didn't post terrible earnings, but weak guidance is weighing heavily, especially in the absence of FII DIIs have already used most of their cash, their incremental buying will depend on the inflow from SIPs and earnings results. So companies with strong earnings and forward guidance will likely get DII if the early festival season gives good signs on the consumption front, that could also be a positive trigger. Until then, expect the market to remain in a sideways, consolidative phase for some time.
